

Ronald C Petersen

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/6309328/publications.pdf](https://exaly.com/author-pdf/6309328/publications.pdf)

Version: 2024-02-01

525
papers

63,485
citations

1695

104
h-index

1198

228
g-index

577
all docs

577
docs citations

577
times ranked

55461
citing authors

#	ARTICLE	IF	CITATIONS
1	TMEM106B core deposition associates with TDP-43 pathology and is increased in risk SNP carriers for frontotemporal dementia. <i>Science Translational Medicine</i> , 2024, 16, .	13.4	5
2	Machine Learning Models of Polygenic Risk for Enhanced Prediction of Alzheimer Disease Endophenotypes. <i>Neurology: Genetics</i> , 2024, 10, .	2.5	1
3	Author Response: Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging. <i>Neurology</i> , 2024, 102, .	1.1	0
4	Boston Criteria v2.0 for Cerebral Amyloid Angiopathy Without Hemorrhage. <i>Neurology</i> , 2024, 102, .	1.1	1
5	Gliovascular transcriptional perturbations in Alzheimer's disease reveal molecular mechanisms of blood brain barrier dysfunction. <i>Nature Communications</i> , 2024, 15, .	13.2	0
6	CYP11B1-RMDN2 Alzheimer's disease endophenotype locus identified for cerebral tau PET. <i>Nature Communications</i> , 2024, 15, .	13.2	0
7	Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging. <i>Alzheimer's and Dementia</i> , 2023, 19, 4498-4506.	0.7	21
8	Association of Indication for Hospitalization With Subsequent Amyloid Positron Emission Tomography and Magnetic Resonance Imaging Biomarkers. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2023, 78, 304-313.	3.7	0
9	White Matter Degeneration Pathways Associated With Tau Deposition in Alzheimer Disease. <i>Neurology</i> , 2023, 100, .	1.1	10
10	Evidence against a temporal association between cerebrovascular disease and Alzheimer's disease imaging biomarkers. <i>Nature Communications</i> , 2023, 14, .	13.2	4
11	Clinicoradiologic and Neuropathologic Evaluation of Corticobasal Syndrome. <i>Neurology</i> , 2023, 101, .	1.1	12
12	Association of Polysomnographic Sleep Parameters With Neuroimaging Biomarkers of Cerebrovascular Disease in Older Adults With Sleep Apnea. <i>Neurology</i> , 2023, 101, .	1.1	7
13	β -Amyloid Load on PET Along the Continuum of Dementia With Lewy Bodies. <i>Neurology</i> , 2023, 101, .	1.1	6
14	Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort. <i>Neurology</i> , 2023, 101, .	1.1	22
15	Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging. <i>Neurology</i> , 2023, 101, .	1.1	38
16	Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial. <i>Nature Medicine</i> , 2023, 29, 2481-2488.	30.1	51
17	Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline. <i>Alzheimer's and Dementia</i> , 2022, 18, 602-611.	0.7	29
18	Detection of Alzheimer's disease amyloid beta 1-42, p-tau, and t-tau assays. <i>Alzheimer's and Dementia</i> , 2022, 18, 635-644.	0.7	38

#	ARTICLE	IF	CITATIONS
19	Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. <i>Alzheimer's and Dementia</i> , 2022, 18, 1128-1140.	0.7	115
20	Medical and nursing home costs: From cognitively unimpaired through dementia. <i>Alzheimer's and Dementia</i> , 2022, 18, 393-407.	0.7	2
21	Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 824-857.	0.7	71
22	Regional Brain Stiffness Analysis of Dementia with Lewy Bodies. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 55, 1907-1909.	3.6	1
23	Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. <i>Brain</i> , 2022, 145, 27-44.	8.0	52
24	Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2022, 18, 1370-1382.	0.7	22
25	Cerebrospinal fluid dynamics and discordant amyloid biomarkers. <i>Neurobiology of Aging</i> , 2022, 110, 27-36.	3.2	10
26	The temporal onset of the core features in dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2022, 18, 591-601.	0.7	23
27	Clinical Deep Phenotyping of <i>ABCA7</i> Mutation Carriers. <i>Neurology: Genetics</i> , 2022, 8, e655.	2.5	8
28	Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk. <i>Brain Communications</i> , 2022, 4, fcac017.	3.4	20
29	¹ H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults. <i>Neurobiology of Aging</i> , 2022, 112, 16-26.	3.2	12
30	TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration. <i>NeuroImage: Clinical</i> , 2022, 34, 102954.	2.8	8
31	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. <i>Brain Communications</i> , 2022, 4, fcac013.	3.4	16
32	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. <i>Acta Neuropathologica Communications</i> , 2022, 10, 16.	5.4	19
33	Are plasma markers for Alzheimer's disease ready for clinical use?. <i>Nature Aging</i> , 2022, 2, 94-96.	8.5	1
34	TDP-43 represses cryptic exon inclusion in the FTD-ALS gene <i>UNC13A</i> . <i>Nature</i> , 2022, 603, 124-130.	36.2	243
35	Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimer's disease: a series of clinical cases. <i>Journal of Neurology</i> , 2022, 269, 4110-4128.	3.8	9
36	Screening and enrollment of underrepresented ethnocultural and educational populations in the Alzheimer's Disease Neuroimaging Initiative (ADNI). <i>Alzheimer's and Dementia</i> , 2022, 18, 2603-2613.	0.7	12

#	ARTICLE	IF	CITATIONS
37	Reply to A Letter Concerning "Aducanumab: What About the Patient?", <i>Annals of Neurology</i> , 2022, 91, 733-734.	5.8	0
38	Detecting Alzheimer Disease Clinically. <i>Neurology</i> , 2022, 98, 607-608.	1.1	1
39	Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies. <i>Movement Disorders</i> , 2022, 37, 1256-1264.	4.3	13
40	Poly (ADP-Ribose) and "synuclein extracellular vesicles in patients with Parkinson disease: A possible biomarker of disease severity. <i>PLoS ONE</i> , 2022, 17, e0264446.	2.5	9
41	A longitudinal investigation of A β ² , anxiety, depression, and mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2022, 18, 1824-1831.	0.7	20
42	Shared brain transcriptomic signature in TDP-43 type A FTLN patients with or without <i>GRN</i> mutations. <i>Brain</i> , 2022, 145, 2472-2485.	8.0	6
43	Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2022, 143, 571-583.	7.9	4
44	Deep learning-based brain age prediction in normal aging and dementia. <i>Nature Aging</i> , 2022, 2, 412-424.	8.5	77
45	Frequency and distribution of TAR DNA-binding protein 43 (TDP-43) pathology increase linearly with age in a large cohort of older adults with and without dementia. <i>Acta Neuropathologica</i> , 2022, 144, 159-160.	7.9	15
46	Artificial Intelligence-Enabled Electrocardiogram for Atrial Fibrillation Identifies Cognitive Decline Risk and Cerebral Infarcts. <i>Mayo Clinic Proceedings</i> , 2022, 97, 871-880.	2.8	7
47	Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 1537-1547.	2.7	6
48	Autosomal dominant and sporadic late onset Alzheimer's disease share a common <i>in vivo</i> pathophysiology. <i>Brain</i> , 2022, 145, 3594-3607.	8.0	26
49	Performance of plasma phosphorylated tau 181 and 217 in the community. <i>Nature Medicine</i> , 2022, 28, 1398-1405.	30.1	154
50	Alzheimer's disease cerebrospinal fluid biomarkers differentiate patients with Creutzfeldt-Jakob disease and autoimmune encephalitis. <i>European Journal of Neurology</i> , 2022, 29, 2905-2912.	3.6	5
51	Prediction of Incident Dementia Using Patient Temporal Health Status. <i>Studies in Health Technology and Informatics</i> , 2022, , .	0.0	1
52	Polygenic Scores of Alzheimer's Disease Risk Genes Add Only Modestly to APOE in Explaining Variation in Amyloid PET Burden. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1615-1625.	2.7	4
53	Optimum Differentiation of Frontotemporal Lobar Degeneration from Alzheimer Disease Achieved with Cross-Sectional Tau Positron Emission Tomography. <i>Annals of Neurology</i> , 2022, 92, 1016-1029.	5.8	4
54	Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. <i>Nature Medicine</i> , 2022, 28, 2381-2387.	30.1	150

#	ARTICLE	IF	CITATIONS
55	Brain Regional Glucose Metabolism, Neuropsychiatric Symptoms, and the Risk of Incident Mild Cognitive Impairment: The Mayo Clinic Study of Aging. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 179-191.	1.1	29
56	Association of Hospitalization with Long-Term Cognitive Trajectories in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 660-668.	2.9	21
57	Association between surgery with anesthesia and cognitive decline in older adults: Analysis using shared parameter models for informative dropout. <i>Journal of Clinical and Translational Science</i> , 2021, 5, e27.	0.7	3
58	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. <i>NeuroImage</i> , 2021, 224, 117433.	4.4	69
59	Association of Initial β -Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. <i>JAMA Neurology</i> , 2021, 78, 217.	9.3	34
60	Brain MRI after critical care admission: A longitudinal imaging study. <i>Journal of Critical Care</i> , 2021, 62, 117-123.	2.3	8
61	Physical Activity and Trajectory of Cognitive Change in Older Persons: Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 377-388.	2.7	14
62	The value of multimodal imaging with ^{123}I -FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia. <i>Neurobiology of Aging</i> , 2021, 99, 11-18.	3.2	13
63	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel. <i>JAMA Neurology</i> , 2021, 78, 102.	9.3	166
64	Association of Cortical and Subcortical β -Amyloid With Standardized Measures of Depressive and Anxiety Symptoms in Adults Without Dementia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2021, 33, 64-71.	2.0	9
65	Mayo Normative Studies: Regression-Based Normative Data for the Auditory Verbal Learning Test for Ages 30-91 Years and the Importance of Adjusting for Sex. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 211-226.	2.3	39
66	β -Amyloid PET and ^{123}I -FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. <i>Neurology</i> , 2021, 96, .	1.1	14
67	FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. <i>NeuroImage: Clinical</i> , 2021, 31, 102754.	2.8	30
68	Detection of β -amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers. <i>Brain Communications</i> , 2021, 3, fcab008.	3.4	55
69	Gait Speed and Instrumental Activities of Daily Living in Older Adults After Hospitalization: A Longitudinal Population-Based Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, e272-e280.	3.7	1
70	Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimer's pathophysiology. <i>Acta Neuropathologica Communications</i> , 2021, 9, 48.	5.4	20
71	National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome. <i>Neurology</i> , 2021, 96, 848-863.	1.1	178
72	Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers. <i>Alzheimer's and Dementia</i> , 2021, 17, 801-812.	0.7	20

#	ARTICLE	IF	CITATIONS
73	TAR DNA-Binding Protein 43 Is Associated with Rate of Memory, Functional and Global Cognitive Decline in the Decade Prior to Death. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 683-693.	2.7	10
74	Neuropsychiatric symptoms and the outcome of cognitive trajectories in older adults free of dementia: The Mayo Clinic Study of Aging. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1362-1369.	2.7	25
75	Diagnostic accuracy of the Cogstate Brief Battery for prevalent MCI and prodromal AD (MCI) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.7	20
76	White matter abnormalities are key components of cerebrovascular disease impacting cognitive decline. <i>Brain Communications</i> , 2021, 3, fcab076.	3.4	18
77	<scp>NIAâ€œAA</scp> Alzheimer's Disease Framework: Clinical Characterization of Stages. <i>Annals of Neurology</i> , 2021, 89, 1145-1156.	5.8	36
78	Diffusion models reveal white matter microstructural changes with ageing, pathology and cognition. <i>Brain Communications</i> , 2021, 3, fcab106.	3.4	46
79	Long-read targeted sequencing uncovers clinicopathological associations for <i>C9orf72</i>-linked diseases. <i>Brain</i> , 2021, 144, 1082-1088.	8.0	21
80	Transcriptomic analysis to identify genes associated with selective hippocampal vulnerability in Alzheimerâ€™s disease. <i>Nature Communications</i> , 2021, 12, 2311.	13.2	52
81	Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 113-122.	2.7	13
82	MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease. <i>Journal of Neuroimaging</i> , 2021, 31, 1020-1027.	2.0	16
83	Changing the face of neuroimaging research: Comparing a new MRI de-facing technique with popular alternatives. <i>NeuroImage</i> , 2021, 231, 117845.	4.4	47
84	CSF dynamics as a predictor of cognitive progression. <i>NeuroImage</i> , 2021, 232, 117899.	4.4	4
85	Lipidomic Network of Mild Cognitive Impairment from the Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 533-543.	2.7	4
86	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. <i>Brain</i> , 2021, 144, 3212-3225.	8.0	29
87	Cerebral Microbleeds. <i>Stroke</i> , 2021, 52, 2347-2355.	5.3	10
88	Lack of physical activity, neuropsychiatric symptoms and the risk of incident mild cognitive impairment in older community-dwelling individuals. <i>German Journal of Exercise and Sport Research</i> , 2021, 51, 487-494.	1.3	7
89	Aducanumab: What about the Patient?. <i>Annals of Neurology</i> , 2021, 90, 334-335.	5.8	12
90	Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET. <i>Brain Communications</i> , 2021, 3, fcab182.	3.4	15

#	ARTICLE	IF	CITATIONS
91	Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid- β PET Signal. <i>Neurology</i> , 2021, 97, e1799-e1808.	1.1	11
92	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. <i>NeuroImage</i> , 2021, 238, 118259.	4.4	29
93	Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. <i>JAMA Neurology</i> , 2021, 78, 1108.	9.3	131
94	Pilot Evaluation of the Unsupervised, At-Home Cogstate Brief Battery in ADNI-2. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 915-925.	2.7	10
95	A Comparison of Cross-Sectional and Longitudinal Methods of Defining Objective Subtle Cognitive Decline in Preclinical Alzheimer's Disease Based on Cogstate One Card Learning Accuracy Performance. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 861-877.	2.7	8
96	<i>APOE3</i> -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. <i>Science Translational Medicine</i> , 2021, 13, eabc9375.	13.4	46
97	Sex Difference in the Relation Between Marital Status and Dementia Risk in Two Population-Based Cohorts. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1269-1279.	2.7	9
98	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2021, 105, 252-261.	3.2	18
99	Relationships between β -amyloid and tau in an elderly population: An accelerated failure time model. <i>NeuroImage</i> , 2021, 242, 118440.	4.4	19
100	Longitudinal deterioration of white-matter integrity: heterogeneity in the ageing population. <i>Brain Communications</i> , 2021, 3, fcaa238.	3.4	13
101	Reply to "Thinking beyond Aducanumab Controversy". <i>Annals of Neurology</i> , 2021, 90, 1004-1004.	5.8	0
102	Connecting Cohorts to Diminish Alzheimer's Disease (CONCORD-AD): A Report of an International Research Collaboration Network. <i>Journal of Alzheimer's Disease</i> , 2021, , 1-15.	2.7	1
103	Longitudinally Increasing Elevated Asymmetric Flortaucipir Binding in a Cognitively Unimpaired Amyloid-Negative Older Individual. <i>Journal of Alzheimer's Disease</i> , 2021, , 1-6.	2.7	1
104	Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 199.	6.4	40
105	CSF and blood plasma mass spectrometry measures of $A\beta$, tau, and NfL species and longitudinal relationship to preclinical and clinical staging of amyloid and tau aggregation and clinical stage of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.7	2
106	The Overlap Index: A new means for early detection of serial tau PET signal change. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.7	0
107	Early Alert of Elderly Cognitive Impairment using Temporal Streaming Clustering. , 2021, 2021, 905-912.		3
108	The screening and enrollment of underrepresented ethn racial and educational populations in the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.7	1

#	ARTICLE	IF	CITATIONS
109	Diffusion models reveal white matter microstructural changes with aging, pathology, and cognition. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.7	0
110	Successful cognitive aging definitions and associated demographic, biomarker profiles and lifestyles in the 80+ MCSA population. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.7	0
111	Cardiorespiratory Fitness and Brain Volumes. <i>Mayo Clinic Proceedings</i> , 2020, 95, 6-8.	2.8	6
112	Linear vs volume measures of ventricle size. <i>Neurology</i> , 2020, 94, e549-e556.	1.1	21
113	Cerebral microbleed incidence, relationship to amyloid burden. <i>Neurology</i> , 2020, 94, e190-e199.	1.1	34
114	Brain imaging measurements of fibrillar amyloid β burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the <i>APOE</i> μ 4 allele. <i>Alzheimer's and Dementia</i> , 2020, 16, 598-609.	0.7	26
115	Incidence of frontotemporal disorders in Olmsted County: A population-based study. <i>Alzheimer's and Dementia</i> , 2020, 16, 482-490.	0.7	12
116	Tau β -positron emission tomography correlates with neuropathology findings. <i>Alzheimer's and Dementia</i> , 2020, 16, 561-571.	0.7	128
117	Longitudinal flortaucipir ([¹⁸ F]AV-1451) PET imaging in primary progressive apraxia of speech. <i>Cortex</i> , 2020, 124, 33-43.	2.7	6
118	β -Amyloid PET and neuropathology in dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, e282-e291.	1.1	69
119	β -Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. <i>Neurology</i> , 2020, 95, e3257-e3268.	1.1	68
120	Predicting future rates of tau accumulation on PET. <i>Brain</i> , 2020, 143, 3136-3150.	8.0	78
121	Reduced fractional anisotropy of the genu of the corpus callosum as a cerebrovascular disease marker and predictor of longitudinal cognition in MCI. <i>Neurobiology of Aging</i> , 2020, 96, 176-183.	3.2	36
122	Variants in <i>PPP2R2B</i> and <i>IGF2BP3</i> are associated with higher tau deposition. <i>Brain Communications</i> , 2020, 2, fcaa159.	3.4	13
123	Artificial Intelligence–Electrocardiography to Predict Incident Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e009355.	5.0	78
124	Genome-wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2020, 16, 1213-1223.	0.7	27
125	Association of <i>ABI3</i> and <i>PLCG2</i> missense variants with disease risk and neuropathology in Lewy body disease and progressive supranuclear palsy. <i>Acta Neuropathologica Communications</i> , 2020, 8, 172.	5.4	10
126	Association Between Neuropsychiatric Symptoms and Functional Change in Older Non-Demented Adults: Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 911-917.	2.7	3

#	ARTICLE	IF	CITATIONS
127	Associations Between Plasma Ceramides and Cerebral Microbleeds or Lacunes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2785-2793.	4.7	10
128	Tau and apolipoprotein E modulate cerebrovascular tight junction integrity independent of cerebral amyloid angiopathy in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, 1372-1383.	0.7	41
129	NIA's AD framework stage 2: Performance in the community. <i>Alzheimer's and Dementia</i> , 2020, 16, e040262.	0.7	0
130	MAPT subhaplotypes in corticobasal degeneration: assessing associations with disease risk, severity of tau pathology, and clinical features. <i>Acta Neuropathologica Communications</i> , 2020, 8, 218.	5.4	12
131	Protein contributions to brain atrophy acceleration in Alzheimer's disease and primary age-related tauopathy. <i>Brain</i> , 2020, 143, 3463-3476.	8.0	54
132	Cortical atrophy patterns of incident MCI subtypes in the Mayo Clinic Study of Aging. <i>Alzheimer's and Dementia</i> , 2020, 16, 1013-1022.	0.7	24
133	Prevalence and Heterogeneity of Cerebrovascular Disease Imaging Lesions. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1195-1205.	2.8	36
134	Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. <i>Neurology</i> , 2020, 95, e23-e34.	1.1	33
135	Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes. <i>Brain</i> , 2020, 143, 2281-2294.	8.0	58
136	Diagnostic and Prognostic Accuracy of the Cogstate Brief Battery and Auditory Verbal Learning Test in Preclinical Alzheimer's Disease and Incident Mild Cognitive Impairment: Implications for Defining Subtle Objective Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 261-274.	2.7	29
137	Subtypes of dementia with Lewy bodies are associated with α -synuclein and tau distribution. <i>Neurology</i> , 2020, 95, e155-e165.	1.1	52
138	Exposure to surgery with general anaesthesia during adult life is not associated with increased brain amyloid deposition in older adults. <i>British Journal of Anaesthesia</i> , 2020, 124, 594-602.	3.3	18
139	Preoperative cognitive impairment associated with oversedation during recovery from anesthesia. <i>Journal of Anesthesia</i> , 2020, 34, 390-396.	1.8	3
140	Witnessed apneas are associated with elevated tau-PET levels in cognitively unimpaired elderly. <i>Neurology</i> , 2020, 94, e1793-e1802.	1.1	30
141	CSF biomarkers in Olmsted County. <i>Neurology</i> , 2020, 95, e256-e267.	1.1	15
142	Longitudinal flortaucipir ([¹⁸ F]AV-1451) PET uptake in semantic dementia. <i>Neurobiology of Aging</i> , 2020, 92, 135-140.	3.2	3
143	¹⁸ F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. <i>Brain Communications</i> , 2020, 2, fcaa040.	3.4	18
144	A soluble truncated tau species related to cognitive dysfunction is elevated in the brain of cognitively impaired human individuals. <i>Scientific Reports</i> , 2020, 10, 3869.	3.4	27

#	ARTICLE	IF	CITATIONS
145	Better stress coping associated with lower tau in amyloid-positive cognitively unimpaired older adults. <i>Neurology</i> , 2020, 94, e1571-e1579.	1.1	20
146	Medical Doctors and Dementia: A Longitudinal Study. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1250-1255.	2.9	1
147	Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. <i>Annals of Neurology</i> , 2020, 87, 556-567.	5.8	19
148	Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimer's Disease Neuropathological Changes. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1511-1523.	2.7	17
149	TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease. <i>Journal of Neurology</i> , 2020, 267, 1444-1453.	3.8	4
150	International drive to illuminate delirium: A developing public health blueprint for action. <i>Alzheimer's and Dementia</i> , 2020, 16, 711-725.	0.7	37
151	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 707-721.	3.7	17
152	Brain amyloid, cortical thickness, and changes in activities of daily living. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 474-485.	3.7	3
153	Association between transactive response DNA-binding protein of 43 kDa type and cognitive resilience to Alzheimer's disease: a case-control study. <i>Neurobiology of Aging</i> , 2020, 92, 92-97.	3.2	15
154	The quest for dementia prevention does not include an aspirin a day. <i>Neurology</i> , 2020, 95, 105-106.	1.1	2
155	Pick's disease: clinicopathologic characterization of 21 cases. <i>Journal of Neurology</i> , 2020, 267, 2697-2704.	3.8	20
156	Associations between cerebrospinal fluid total phosphatidylcholines, neurodegeneration, cognitive decline, and risk of mild cognitive impairment in the Mayo Clinic Study of Aging. <i>Neurobiology of Aging</i> , 2020, 93, 52-54.	3.2	1
157	Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. <i>Journal of Clinical Investigation</i> , 2020, 130, 6080-6092.	8.2	137
158	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2020, 8, 5.	5.4	27
159	Longitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes. <i>Neurology</i> , 2020, 95, e3190-e3202.	1.1	18
160	The Association of Multimorbidity With Preclinical AD Stages and SNAP in Cognitively Unimpaired Persons. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 877-883.	3.7	17
161	Association of non-exercise physical activity in mid- and late-life with cognitive trajectories and the impact of APOE ϵ 4 genotype status: the Mayo Clinic Study of Aging. <i>European Journal of Ageing</i> , 2019, 16, 491-502.	2.7	9
162	Informant-based hearing difficulties and the risk for mild cognitive impairment and dementia. <i>Age and Ageing</i> , 2019, 48, 888-894.	1.6	15

#	ARTICLE	IF	CITATIONS
163	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging's Alzheimer's Association Research Framework. <i>JAMA Neurology</i> , 2019, 76, 1174.	9.3	201
164	Comparison of the Short Test of Mental Status and the Montreal Cognitive Assessment Across the Cognitive Spectrum. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1516-1523.	2.8	37
165	Exposure to surgery under general anaesthesia and brain magnetic resonance imaging changes in older adults. <i>British Journal of Anaesthesia</i> , 2019, 123, 808-817.	3.3	13
166	Extensive transcriptomic study emphasizes importance of vesicular transport in C9orf72 expansion carriers. <i>Acta Neuropathologica Communications</i> , 2019, 7, 150.	5.4	45
167	Association of Apolipoprotein E ϵ 4, Educational Level, and Sex With Tau Deposition and Tau-Mediated Metabolic Dysfunction in Older Adults. <i>JAMA Network Open</i> , 2019, 2, e1913909.	6.0	45
168	Amyloid, Vascular, and Resilience Pathways Associated with Cognitive Aging. <i>Annals of Neurology</i> , 2019, 86, 866-877.	5.8	46
169	Incidence of Convexal Subarachnoid Hemorrhage in the Elderly: The Mayo Clinic Study of Aging. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 104451.	1.6	1
170	Comparison of variables associated with cerebrospinal fluid neurofilament, total τ , and neurogranin. <i>Alzheimer's and Dementia</i> , 2019, 15, 1437-1447.	0.7	43
171	Population-Based Evaluation of Lumbar Puncture Opening Pressures. <i>Frontiers in Neurology</i> , 2019, 10, 899.	2.5	25
172	The bivariate distribution of amyloid- β 2 and tau: relationship with established neurocognitive clinical syndromes. <i>Brain</i> , 2019, 142, 3230-3242.	8.0	139
173	Cognitive function after surgery with regional or general anesthesia: A population-based study. <i>Alzheimer's and Dementia</i> , 2019, 15, 1243-1252.	0.7	15
174	Cardiometabolic Health and Longitudinal Progression of White Matter Hyperintensity. <i>Stroke</i> , 2019, 50, 3037-3044.	5.3	44
175	Elevated Plasma Ceramides Are Associated With Higher White Matter Hyperintensity Volume—Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 2431-2436.	4.7	10
176	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. <i>Brain</i> , 2019, 142, 3621-3635.	8.0	42
177	Factors Associated With Meningioma Detected in a Population-Based Sample. <i>Mayo Clinic Proceedings</i> , 2019, 94, 254-261.	2.8	7
178	The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals. <i>Neurobiology of Aging</i> , 2019, 77, 26-36.	3.2	53
179	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. <i>Acta Neuropathologica</i> , 2019, 138, 237-250.	7.9	94
180	Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome. <i>Brain</i> , 2019, 142, 2466-2482.	8.0	37

#	ARTICLE	IF	CITATIONS
181	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2316.	7.0	241
182	Neuropsychological subtypes of incident mild cognitive impairment in the Mayo Clinic Study of Aging. <i>Alzheimer's and Dementia</i> , 2019, 15, 878-887.	0.7	44
183	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 927-939.	0.7	59
184	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. <i>Neurology</i> , 2019, 93, e29-e39.	1.1	71
185	Plasma and CSF neurofilament light. <i>Neurology</i> , 2019, 93, e252-e260.	1.1	180
186	White matter hyperintensities: relationship to amyloid and tau burden. <i>Brain</i> , 2019, 142, 2483-2491.	8.0	147
187	Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 23, 101823.	2.8	60
188	A brief history of "Alzheimer disease". <i>Neurology</i> , 2019, 92, 1053-1059.	1.1	60
189	Brain atrophy in primary age-related tauopathy is linked to transactive response DNA-binding protein of 43 kDa. <i>Alzheimer's and Dementia</i> , 2019, 15, 799-806.	0.7	17
190	Association of <i>MAPT</i> Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology. <i>JAMA Neurology</i> , 2019, 76, 710.	9.3	43
191	The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies. <i>Brain</i> , 2019, 142, 1134-1147.	8.0	78
192	<i>CSF1R</i> mutation presenting as dementia with Lewy bodies. <i>Neurocase</i> , 2019, 25, 17-20.	0.7	9
193	Cortical β -amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging. <i>Translational Psychiatry</i> , 2019, 9, 123.	4.9	59
194	Amyloid PET and Changes in Clinical Management for Patients With Cognitive Impairment. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1258.	7.0	8
195	Longitudinal association between phosphatidylcholines, neuroimaging measures of Alzheimer's disease pathophysiology, and cognition in the Mayo Clinic Study of Aging. <i>Neurobiology of Aging</i> , 2019, 79, 43-49.	3.2	7
196	Heritability and genetic variance of dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2019, 127, 492-501.	4.5	29
197	Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2019, 34, 1144-1153.	4.3	105
198	Genome-wide analyses as part of the international FTLTDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLTDP. <i>Acta Neuropathologica</i> , 2019, 137, 879-899.	7.9	96

#	ARTICLE	IF	CITATIONS
199	Selective loss of cortical endothelial tight junction proteins during Alzheimer's disease progression. <i>Brain</i> , 2019, 142, 1077-1092.	8.0	129
200	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	20.4	2,145
201	Entorhinal cortex tau, amyloid- β , cortical thickness and memory performance in non-demented subjects. <i>Brain</i> , 2019, 142, 1148-1160.	8.0	71
202	ICP-086: CORTICAL ATROPHY PATTERNS OF EMPIRICALLY DERIVED INCIDENT MCI SUBTYPES IN THE MAYO CLINIC STUDY OF AGING. <i>Alzheimer's and Dementia</i> , 2019, 15, P76.	0.7	0
203	Functional Activity and Neuropsychiatric Symptoms in Normal Aging and Mild Cognitive Impairment. <i>Alzheimer Disease and Associated Disorders</i> , 2019, 33, 68-71.	1.3	8
204	Deep Learning Prediction of Mild Cognitive Impairment using Electronic Health Records. , 2019, 2019, 799-806.		17
205	Quantity and quality of mental activities and the risk of incident mild cognitive impairment. <i>Neurology</i> , 2019, 93, e548-e558.	1.1	42
206	Cerebrospinal fluid dynamics disorders. <i>Neurology</i> , 2019, 93, e2237-e2246.	1.1	21
207	ICP-022: BRAIN STATES AND TALI PET PATTERNS INTERACT ACROSS THE AGING-ALZHEIMER'S CONTINUUM. <i>Alzheimer's and Dementia</i> , 2019, 15, P30.	0.7	0
208	Association Between Critical Care Admissions and Cognitive Trajectories in Older Adults*. <i>Critical Care Medicine</i> , 2019, 47, 1116-1124.	0.9	22
209	Association of Longitudinal β -Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. <i>JAMA Network Open</i> , 2019, 2, e1916439.	6.0	26
210	Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. <i>Acta Neuropathologica</i> , 2019, 137, 227-238.	7.9	71
211	Cerebral microbleeds. <i>Neurology</i> , 2019, 92, e253-e262.	1.1	55
212	Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment. <i>JAMA Neurology</i> , 2019, 76, 187.	9.3	71
213	MRI Outperforms [¹⁸ F]AV-1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2019, 34, 105-113.	4.3	37
214	¹⁸ F-AV-1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy. <i>Movement Disorders</i> , 2019, 34, 344-352.	4.3	26
215	The influence of β -amyloid on [¹⁸ F]AV-1451 in semantic variant of primary progressive aphasia. <i>Neurology</i> , 2019, 92, e710-e722.	1.1	11
216	Multisite study of the relationships between <i>antemortem</i> [¹¹ C]PIB-PET Centiloid values and <i>postmortem</i> measures of Alzheimer's disease neuropathology. <i>Alzheimer's and Dementia</i> , 2019, 15, 205-216.	0.7	178

#	ARTICLE	IF	CITATIONS
217	Automated and manual hippocampal segmentation techniques: Comparison of results, reproducibility and clinical applicability. <i>NeuroImage: Clinical</i> , 2019, 21, 101574.	2.8	12
218	A comprehensive screening of copy number variability in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2019, 75, 223.e1-223.e10.	3.2	13
219	Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2019, 15, 106-152.	0.7	330
220	Distinct cytokine profiles in human brains resilient to Alzheimer's pathology. <i>Neurobiology of Disease</i> , 2019, 121, 327-337.	4.5	90
221	Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe Neurodegeneration. <i>JAMA Neurology</i> , 2019, 76, 95.	9.3	79
222	Predicting Progression to Mild Cognitive Impairment. <i>Annals of Neurology</i> , 2019, 85, 155-160.	5.8	34
223	Comparison of PC and iPad administrations of the Cogstate Brief Battery in the Mayo Clinic Study of Aging: Assessing cross-modality equivalence of computerized neuropsychological tests. <i>Clinical Neuropsychologist</i> , 2019, 33, 1102-1126.	3.0	16
224	A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 181-195.	2.7	50
225	Automated detection of imaging features of disproportionately enlarged subarachnoid space hydrocephalus using machine learning methods. <i>NeuroImage: Clinical</i> , 2019, 21, 101605.	2.8	29
226	The Cross-sectional and Longitudinal Associations Between IL-6, IL-10, and TNF α and Cognitive Outcomes in the Mayo Clinic Study of Aging. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 1289-1295.	3.7	49
227	Relationship Between Risk Factors and Brain Reserve in Late Middle Age: Implications for Cognitive Aging. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 355.	3.5	28
228	The association between peripheral total IGF-1, IGFBP-3, and IGF-1/IGFBP-3 and functional and cognitive outcomes in the Mayo Clinic Study of Aging. <i>Neurobiology of Aging</i> , 2018, 66, 68-74.	3.2	33
229	Joint associations of β 2-amyloidosis and cortical thickness with cognition. <i>Neurobiology of Aging</i> , 2018, 65, 121-131.	3.2	28
230	White Matter Reference Region in PET Studies of ^{11}C -Pittsburgh Compound B Uptake: Effects of Age and Amyloid- β Deposition. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1583-1589.	6.1	41
231	Frequency of Acute and Subacute Infarcts in a Population-Based Study. <i>Mayo Clinic Proceedings</i> , 2018, 93, 300-306.	2.8	5
232	Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau and amyloid- β positron emission tomography. <i>Alzheimer's and Dementia</i> , 2018, 14, 989-997.	0.7	427
233	Leisure-Time Physical Activity and the Risk of Incident Dementia: The Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 149-155.	2.7	35
234	The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable. <i>Alzheimer's and Dementia</i> , 2018, 14, 563-575.	0.7	102

#	ARTICLE	IF	CITATIONS
235	Elevated medial temporal lobe and pervasive brain tau-PET signal in normal participants. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 210-216.	2.6	22
236	[¹⁸ F]AV-1451 tau-PET and primary progressive aphasia. <i>Annals of Neurology</i> , 2018, 83, 599-611.	5.8	76
237	Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech. <i>Cortex</i> , 2018, 99, 358-374.	2.7	44
238	Tau-negative amnesic dementia masquerading as Alzheimer disease dementia. <i>Neurology</i> , 2018, 90, e940-e946.	1.1	29
239	In vivo ¹⁸ F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. <i>Neurology</i> , 2018, 90, e947-e954.	1.1	61
240	Sex differences in cerebrovascular pathologies on FLAIR in cognitively unimpaired elderly. <i>Neurology</i> , 2018, 90, e466-e473.	1.1	62
241	Potentially Modifiable Risk Factors for Long-Term Cognitive Impairment After Critical Illness: A Systematic Review. <i>Mayo Clinic Proceedings</i> , 2018, 93, 68-82.	2.8	73
242	Practice guideline update summary: Mild cognitive impairment [RETIRED]. <i>Neurology</i> , 2018, 90, 126-135.	1.1	1,409
243	Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2018, 48, 3-9.	2.2	27
244	[¹⁸ F]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. <i>Annals of Neurology</i> , 2018, 83, 248-257.	5.8	75
245	Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. <i>Brain</i> , 2018, 141, 271-287.	8.0	234
246	Longitudinal Association Between Brain Amyloid-Beta and Gait in the Mayo Clinic Study of Aging. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 1244-1250.	3.7	31
247	Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting. <i>JAMA Neurology</i> , 2018, 75, 970.	9.3	131
248	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. <i>Lancet Neurology</i> , 2018, 17, 548-558.	10.4	105
249	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1005-1014.	0.7	85
250	Longitudinal tau PET in ageing and Alzheimer's disease. <i>Brain</i> , 2018, 141, 1517-1528.	8.0	335
251	Disrupted functional connectivity in primary progressive apraxia of speech. <i>NeuroImage: Clinical</i> , 2018, 18, 617-629.	2.8	37
252	Trajectories of plasma IGF-1, IGFBP-3, and their ratio in the Mayo Clinic Study of Aging. <i>Experimental Gerontology</i> , 2018, 106, 67-73.	2.9	15

#	ARTICLE	IF	CITATIONS
253	Association of Excessive Daytime Sleepiness With Longitudinal β -Amyloid Accumulation in Elderly Persons Without Dementia. <i>JAMA Neurology</i> , 2018, 75, 672.	9.3	161
254	FDG-PET in tau-negative amnesic dementia resembles that of autopsy-proven hippocampal sclerosis. <i>Brain</i> , 2018, 141, 1201-1217.	8.0	76
255	Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 739-749.	3.3	38
256	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 64-74.	10.4	205
257	Association Between Microinfarcts and Blood Pressure Trajectories. <i>JAMA Neurology</i> , 2018, 75, 212.	9.3	15
258	Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the Mayo Clinic Study of Aging. <i>International Psychogeriatrics</i> , 2018, 30, 245-251.	1.1	58
259	Conserved brain myelination networks are altered in Alzheimer's and other neurodegenerative diseases. <i>Alzheimer's and Dementia</i> , 2018, 14, 352-366.	0.7	123
260	Pittsburgh compound B (PiB) PET imaging of meningioma and other intracranial tumors. <i>Journal of Neuro-Oncology</i> , 2018, 136, 373-378.	3.0	11
261	Plasma Sphingolipids are Associated With Gait Parameters in the Mayo Clinic Study of Aging. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 960-965.	3.7	21
262	P2â€491: SUBTLE COGNITIVE DYSFUNCTION ON COGSTATE IS ASSOCIATED WITH BIOMARKER POSITIVE STATUS. <i>Alzheimer's and Dementia</i> , 2018, 14, P917.	0.7	0
263	P3â€221: LONGITUDINAL ASSOCIATION BETWEEN PHOSPHATIDYLCHOLINES, NEUROIMAGING MEASURES OF ALZHEIMER'S DISEASE PATHOPHYSIOLOGY, AND COGNITION IN THE MAYO CLINIC STUDY ON AGING. <i>Alzheimer's and Dementia</i> , 2018, 14, P1156.	0.7	0
264	P3â€238: LONGITUDINAL ASSOCIATIONS OF PLASMA NEUROFILAMENT LEVELS WITH AMYLOIDâ€PET, FDGâ€PET, AND COGNITION AMONG NONâ€DEMENTED PARTICIPANTS IN THE MAYO CLINIC STUDY ON AGING. <i>Alzheimer's and Dementia</i> , 2018, 14, P1163.	0.7	0
265	P1â€532: MEASURING LATENT COGNITIVE PROCESSES TO DETECT THE EARLIEST CHANGES IN AD. <i>Alzheimer's and Dementia</i> , 2018, 14, P536.	0.7	0
266	P2â€273: CEREBROSPINAL FLUID NEUROFILAMENT LIGHT PROTEIN AND RISK OF MILD COGNITIVE IMPAIRMENT IN THE MAYO CLINIC STUDY OF AGING. <i>Alzheimer's and Dementia</i> , 2018, 14, P782.	0.7	0
267	P4â€078: CONCORDEâ€AD: AN INTERNATIONAL NETWORK OF COHORTS FOR BETTER UNDERSTANDING OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1465.	0.7	0
268	ICâ€Pâ€144: PRINCIPAL AXES OF PHENOTYPIC VARIABILITY IN ALZHEIMER'S DISEASE DERIVED FROM AN FDGâ€PET BASED, UNSUPERVISED MACHINE LEARNING ALGORITHM. <i>Alzheimer's and Dementia</i> , 2018, 14, P122.	0.7	0
269	F2â€02â€01: NEUROFILAMENT LIGHT CHAIN IN AD IN CSF AND BLOOD. <i>Alzheimer's and Dementia</i> , 2018, 14, P603.	0.7	0
270	P1â€160: ABI3 AND PLGG2 AS RISK FACTORS FOR ALZHEIMER'S DISEASE IN CAUCASIANS AND AFRICAN AMERICANS. <i>Alzheimer's and Dementia</i> , 2018, 14, P339.	0.7	0

#	ARTICLE	IF	CITATIONS
271	O2â€13â€01: INCIDENCE OF CEREBRAL MICROBLEEDS AND AMYLOID BURDEN: THE MAYO CLINIC STUDY OF AGING. Alzheimer's and Dementia, 2018, 14, P652.	0.7	0
272	P1â€139: THE CONTRIBUTION OF SEXâ€SPECIFIC ASSOCIATIONS IN GENETIC STUDIES OF ALZHEIMER'S DISEASE PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P327.	0.7	0
273	ICâ€Pâ€083: DIAGNOSTIC UTILITY OF [18F]AVâ€1451 PET, FDGâ€PET AND MRI TO DIFFERENTIATE THE THREE VARIANTS OF PRIMARY PROGRESSIVE APHASIA. Alzheimer's and Dementia, 2018, 14, P71.	0.7	0
274	ICâ€Pâ€019: LONGITUDINAL ACCUMULATION OF Î²â€AMYLOID ON PET IN DEMENTIA WITH LEWY BODIES AND RELATIONSHIP TO CLINICAL DISEASE PROGRESSION. Alzheimer's and Dementia, 2018, 14, P25.	0.7	0
275	Amyloid- and tau-PET imaging in a familial prion kindred. Neurology: Genetics, 2018, 4, e290.	2.5	4
276	P1â€414: STATINS AND BRAIN HEALTH: MEDICATION EFFECTS ON NEUROIMAGING BIOMARKERS IN OLDER INDIVIDUALS. Alzheimer's and Dementia, 2018, 14, P463.	0.7	0
277	FTS3â€01â€03: U.S. PERSPECTIVE ON CLINICAL AMYLOID IMAGING. Alzheimer's and Dementia, 2018, 14, P1004.	0.7	0
278	P1â€387: PRINCIPAL AXES OF PHENOTYPIC VARIABILITY IN ALZHEIMER'S DISEASE DERIVED FROM AN FDGâ€PET BASED UNSUPERVISED MACHINE LEARNING ALGORITHM. Alzheimer's and Dementia, 2018, 14, P449.	0.7	0
279	P3â€597: MEDIAL TEMPORAL LOBE NEURODEGENERATION OBSERVED IN WOMEN WHO UNDERWENT BILATERAL OOPHORECTOMY BEFORE THE ONSET OF MENOPAUSE. Alzheimer's and Dementia, 2018, 14, P1356.	0.7	0
280	P3â€424: LONGITUDINAL ACCUMULATION OF Î²â€AMYLOID ON PET IN DEMENTIA WITH LEWY BODIES AND RELATIONSHIP TO CLINICAL DISEASE PROGRESSION. Alzheimer's and Dementia, 2018, 14, P1271.	0.7	0
281	P3â€202: TDPâ€43 IN ATYPICAL ALZHEIMER'S DISEASE DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1145.	0.7	0
282	Effect of Cognitive Status on the Receipt of Procedures Requiring Anesthesia and Critical Care Admissions in Older Adults. Mayo Clinic Proceedings, 2018, 93, 1552-1562.	2.8	7
283	Risk Factors for Persistent Cognitive Impairment After Critical Illness, Nested Case-Control Study. Critical Care Medicine, 2018, 46, 1977-1984.	0.9	28
284	Association Between Functional Performance and Alzheimer's Disease Biomarkers in Individuals Without Dementia. Journal of the American Geriatrics Society, 2018, 66, 2274-2281.	2.9	10
285	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	8.0	44
286	Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. Annals of Neurology, 2018, 84, 705-716.	5.8	56
287	Association of Apolipoprotein E Î¼4 With Transactive Response DNA-Binding Protein 43. JAMA Neurology, 2018, 75, 1347.	9.3	65
288	P2â€407: COGNITIVE RESILIENCE IN 80+: PREDICTORS AND IMAGING CORRELATES OF COGNITION. Alzheimer's and Dementia, 2018, 14, P863.	0.7	0

#	ARTICLE	IF	CITATIONS
289	ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans. <i>Molecular Neurodegeneration</i> , 2018, 13, 53.	11.8	79
290	Statins and Brain Health: Alzheimer's Disease and Cerebrovascular Disease Biomarkers in Older Adults. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1345-1352.	2.7	25
291	Mediterranean Diet, Its Components, and Amyloid Imaging Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 281-290.	2.7	26
292	Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET. <i>NeuroImage: Clinical</i> , 2018, 19, 939-947.	2.8	34
293	Sex-specific genetic predictors of Alzheimer's disease biomarkers. <i>Acta Neuropathologica</i> , 2018, 136, 857-872.	7.9	94
294	Subjective cognitive decline and risk of MCI. <i>Neurology</i> , 2018, 91, e300-e312.	1.1	191
295	Prosodic and phonetic subtypes of primary progressive apraxia of speech. <i>Brain and Language</i> , 2018, 184, 54-65.	1.7	113
296	Non-right handed primary progressive apraxia of speech. <i>Journal of the Neurological Sciences</i> , 2018, 390, 246-254.	0.6	4
297	Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials. <i>Alzheimer's and Dementia</i> , 2018, 14, 1077-1087.	0.7	90
298	Mild Cognitive Impairment in Geriatrics. <i>Clinics in Geriatric Medicine</i> , 2018, 34, 563-589.	2.4	117
299	<i>APOE</i> ϵ 4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. <i>Neurology</i> , 2018, 91, e1182-e1195.	1.1	133
300	Association of antidiabetic medication use, cognitive decline, and risk of cognitive impairment in older people with type 2 diabetes: Results from the population-based Mayo Clinic Study of Aging. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 1114-1120.	2.7	25
301	Association of telomere length with general cognitive trajectories: a meta-analysis of four prospective cohort studies. <i>Neurobiology of Aging</i> , 2018, 69, 111-116.	3.2	35
302	Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives. <i>Journal of Clinical Investigation</i> , 2018, 128, 1208-1216.	8.2	317
303	Duration and Pathologic Correlates of Lewy Body Disease. <i>JAMA Neurology</i> , 2017, 74, 310.	9.3	50
304	<i>ABCA7</i> loss-of-function variants, expression, and neurologic disease risk. <i>Neurology: Genetics</i> , 2017, 3, e126.	2.5	30
305	A robust biomarker of large-scale network failure in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 152-161.	2.6	29
306	Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). <i>Acta Neuropathologica</i> , 2017, 133, 705-715.	7.9	133

#	ARTICLE	IF	CITATIONS
307	Association Between Mentally Stimulating Activities in Late Life and the Outcome of Incident Mild Cognitive Impairment, With an Analysis of the <i>APOE</i> ϵ 4 Genotype. <i>JAMA Neurology</i> , 2017, 74, 332.	9.3	74
308	Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers. <i>Acta Neuropathologica</i> , 2017, 133, 839-856.	7.9	218
309	Contributions of imprecision in PET \leftrightarrow MRI rigid registration to imprecision in amyloid PET \times SUVR measurements. <i>Human Brain Mapping</i> , 2017, 38, 3323-3336.	3.7	27
310	Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. <i>JAMA Neurology</i> , 2017, 74, 718.	9.3	111
311	Population-Based Prevalence of Cerebral Cavernous Malformations in Older Adults. <i>JAMA Neurology</i> , 2017, 74, 801.	9.3	88
312	Age-specific and sex-specific prevalence of cerebral β -amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. <i>Lancet Neurology</i> , The, 2017, 16, 435-444.	10.4	258
313	Diagnostic dilemmas in Alzheimer's disease: Room for shared decision making. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 301-304.	3.9	31
314	In-depth clinico-pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers. <i>Acta Neuropathologica</i> , 2017, 134, 255-269.	7.9	77
315	Phenoconversion from probable rapid eye movement sleep behavior disorder to mild cognitive impairment to dementia in a population-based sample. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 127-130.	2.6	7
316	Neuroimaging biomarkers and impaired olfaction in cognitively normal individuals. <i>Annals of Neurology</i> , 2017, 81, 871-882.	5.8	53
317	White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 56, 172-179.	3.2	165
318	Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2305.	7.0	332
319	Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. <i>Alzheimer's and Dementia</i> , 2017, 13, e1-e85.	0.7	225
320	Association between tau deposition and antecedent amyloid- β accumulation rates in normal and early symptomatic individuals. <i>Brain</i> , 2017, 140, 1499-1512.	8.0	98
321	Randomized controlled trials in mild cognitive impairment. <i>Neurology</i> , 2017, 88, 1751-1758.	1.1	35
322	Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary report. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 177-188.	3.9	70
323	Brain tau deposition linked to systemic causes of death in normal elderly. <i>Neurobiology of Aging</i> , 2017, 50, 163-166.	3.2	3
324	Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 21-30.	2.6	86

#	ARTICLE	IF	CITATIONS
325	The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. <i>Alzheimer's and Dementia</i> , 2017, 13, 561-571.	0.7	294
326	Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism. <i>Acta Neuropathologica</i> , 2017, 133, 955-966.	7.9	60
327	A candidate regulatory variant at the <i>TREM</i> gene cluster associates with decreased Alzheimer's disease risk and increased <i>TREML1</i> and <i>TREM2</i> brain gene expression. <i>Alzheimer's and Dementia</i> , 2017, 13, 663-673.	0.7	49
328	Prevalence and Natural History of Superficial Siderosis. <i>Stroke</i> , 2017, 48, 3210-3214.	5.3	41
329	Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 60, 92-103.	3.2	72
330	Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. <i>Cortex</i> , 2017, 97, 143-159.	2.7	175
331	Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. <i>Annals of Neurology</i> , 2017, 82, 706-718.	5.8	140
332	Uptake of AV-1451 in meningiomas. <i>Annals of Nuclear Medicine</i> , 2017, 31, 736-743.	2.2	8
333	Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers. <i>Neurology</i> , 2017, 89, 2039-2048.	1.1	15
334	Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study. <i>Lancet Neurology</i> , The, 2017, 16, 917-924.	10.4	166
335	Nursing Home Use Across The Spectrum of Cognitive Decline: Merging Mayo Clinic Study of Aging With CMS MDS Assessments. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 2235-2243.	2.9	2
336	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	20.4	818
337	Neurocognition in individuals with incidentally-identified meningioma. <i>Journal of Neuro-Oncology</i> , 2017, 134, 125-132.	3.0	26
338	Decreased Glutamate Levels in Patients with Amnesic Mild Cognitive Impairment: An sLASER Proton MR Spectroscopy and PiB-PET Study. <i>Journal of Neuroimaging</i> , 2017, 27, 630-636.	2.0	33
339	TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Promote Phase Separation and Alter Stress Granule Dynamics. <i>Neuron</i> , 2017, 95, 808-816.e9.	8.0	519
340	Cortical Thickness and Depressive Symptoms in Cognitively Normal Individuals: The Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 1273-1281.	2.7	16
341	Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging. <i>JAMA Neurology</i> , 2017, 74, 1073.	9.3	157
342	Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease. <i>BMC Medical Genomics</i> , 2017, 10, 29.	1.5	28

#	ARTICLE	IF	CITATIONS
343	Abnormal expression of homeobox genes and transthyretin in <i>C9ORF72</i> expansion carriers. <i>Neurology: Genetics</i> , 2017, 3, e161.	2.5	14
344	¹⁸ F-AV451 tau and ¹²⁵ I-amyloid positron emission tomography imaging in dementia with Lewy bodies. <i>Annals of Neurology</i> , 2017, 81, 58-67.	5.8	156
345	Practice effects and longitudinal cognitive change in clinically normal older adults differ by Alzheimer imaging biomarker status. <i>Clinical Neuropsychologist</i> , 2017, 31, 99-117.	3.0	51
346	[¹⁸ F]AV451 tau positron emission tomography in progressive supranuclear palsy. <i>Movement Disorders</i> , 2017, 32, 124-133.	4.3	138
347	Excessive daytime sleepiness and fatigue may indicate accelerated brain aging in cognitively normal late middle-aged and older adults. <i>Sleep Medicine</i> , 2017, 32, 236-243.	2.3	85
348	Mediterranean diet, micronutrients and macronutrients, and MRI measures of cortical thickness. <i>Alzheimer's and Dementia</i> , 2017, 13, 168-177.	0.7	117
349	FTDP17 with Pick body-like inclusions associated with a novel tau mutation, p.E372G. <i>Brain Pathology</i> , 2017, 27, 612-626.	4.2	11
350	An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 257-266.	0.7	42
351	Cortical Thickness and Anxiety Symptoms Among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2017, 29, 60-66.	2.0	18
352	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2017, 49, 214.e13-214.e15.	3.2	12
353	Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE. <i>NeuroImage</i> , 2017, 144, 113-127.	4.4	61
354	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 205-216.	0.7	653
355	Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 83-91.	3.9	98
356	Tracking the development of agrammatic aphasia: A tensor-based morphometry study. <i>Cortex</i> , 2017, 90, 138-148.	2.7	22
357	Cerebral Amyloid Deposition Is Associated with Gait Parameters in the Mayo Clinic Study of Aging. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 792-799.	2.9	42
358	[P1393]: PATTERN OF HYPOPERFUSION ON ASL OVERLAPS WITH HYPOMETABOLISM ON FDG-PET IN DEMENTIA WITH LEWY BODIES. <i>Alzheimer's and Dementia</i> , 2017, 13, P418.	0.7	0
359	[P2415]: THE MAYO CLINIC ADULT LIFESPAN TEMPLATE: BETTER QUANTIFICATION ACROSS THE LIFESPAN. <i>Alzheimer's and Dementia</i> , 2017, 13, P792.	0.7	33
360	[ICP204]: SUBJECT-LEVEL ASSESSMENT OF REGIONAL CORRELATIONS BETWEEN TAU-PET, AMYLOID-PET, MRI AND FDG-PET ACROSS THE CLINICAL SPECTRUM OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P149.	0.7	0

#	ARTICLE	IF	CITATIONS
361	[F4â€“03â€“04]: INTERVENTIONS FOR PREVENTING COGNITIVE DECLINE AND DEMENTIA: RECOMMENDATIONS FROM A NATIONAL ACADEMIES OF SCIENCES, ENGINEERING, AND MEDICINE STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1214.	0.7	0
362	Distinct spatiotemporal accumulation of N-truncated and full-length amyloid-Î²42 in Alzheimerâ€™s disease. <i>Brain</i> , 2017, 140, 3301-3316.	8.0	14
363	¹ H-MRS metabolites and rate of Î²-amyloid accumulation on serial PET in clinically normal adults. <i>Neurology</i> , 2017, 89, 1391-1399.	1.1	21
364	Creating three dimensional models of Alzheimerâ€™s disease. <i>3D Printing in Medicine</i> , 2017, 3, 13.	3.1	7
365	Novel GRN mutation presenting as an aphasic dementia and evolving into corticobasal syndrome. <i>Neurology: Genetics</i> , 2017, 3, e201.	2.5	2
366	Decreased Expression of Sulfatase 2 in the Brains of Alzheimerâ€™s Disease Patients: Implications for Regulation of Neuronal Cell Signaling. <i>Journal of Alzheimer's Disease Reports</i> , 2017, 1, 115-124.	2.3	16
367	Comparison of [18 F]Flutemetamol and [11 C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals. <i>NeuroImage: Clinical</i> , 2017, 16, 295-302.	2.8	35
368	FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1609-1616.	2.7	35
369	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. <i>Neurology</i> , 2016, 87, 539-547.	1.1	1,317
370	MAPT haplotype diversity in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2016, 30, 40-45.	2.2	23
371	Human whole genome genotype and transcriptome data for Alzheimerâ€™s and other neurodegenerative diseases. <i>Scientific Data</i> , 2016, 3, 160089.	5.4	387
372	First PET Imaging Studies With ⁶³ Zn-Zinc Citrate in Healthy Human Participants and Patients With Alzheimer Disease. <i>Molecular Imaging</i> , 2016, 15, 153601211667379.	1.5	23
373	Serum Adiponectin Levels, Neuroimaging, and Cognition in the Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 573-581.	2.7	69
374	FTS3â€“01: The U.S. National Alzheimerâ€™s Plan: Five Years Later. <i>Alzheimer's and Dementia</i> , 2016, 12, P2780.7	0.7	0
375	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 862-871.	0.7	100
376	RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2016, 45, 107-108.	3.2	21
377	Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimerâ€™s disease. <i>Acta Neuropathologica</i> , 2016, 132, 225-234.	7.9	79
378	Multimorbidity and neuroimaging biomarkers among cognitively normal persons. <i>Neurology</i> , 2016, 86, 2077-2084.	1.1	29

#	ARTICLE	IF	CITATIONS
379	Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. <i>JAMA Neurology</i> , 2016, 73, 721.	9.3	251
380	Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain. <i>Molecular Neurodegeneration</i> , 2016, 11, 31.	11.8	35
381	Soluble sortilin is present in excess and positively correlates with progranulin in CSF of aging individuals. <i>Experimental Gerontology</i> , 2016, 84, 96-100.	2.9	14
382	TYROBP genetic variants in early-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 48, 222.e9-222.e15.	3.2	72
383	TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. <i>Neurology: Genetics</i> , 2016, 2, e85.	2.5	16
384	An autoradiographic evaluation of AV-1451 Tau PET in dementia. <i>Acta Neuropathologica Communications</i> , 2016, 4, 58.	5.4	400
385	Prosaposin is a regulator of progranulin levels and oligomerization. <i>Nature Communications</i> , 2016, 7, 11992.	13.2	74
386	Comparison of Gait Parameters for Predicting Cognitive Decline: The Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 559-567.	2.7	86
387	LRRK2 variation and dementia with Lewy bodies. <i>Parkinsonism and Related Disorders</i> , 2016, 31, 98-103.	2.2	34
388	A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity. <i>NeuroImage: Clinical</i> , 2016, 11, 802-812.	2.8	275
389	Amyloid- β deposition and regional grey matter atrophy rates in dementia with Lewy bodies. <i>Brain</i> , 2016, 139, 2740-2750.	8.0	68
390	Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. <i>Neurology</i> , 2016, 87, 691-698.	1.1	25
391	Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. <i>Neurobiology of Aging</i> , 2016, 46, 32-42.	3.2	22
392	Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort. <i>Alzheimer's and Dementia</i> , 2016, 12, 1226-1234.	0.7	111
393	Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer's disease. <i>BMC Medical Genomics</i> , 2016, 9, 30.	1.5	21
394	Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment. <i>Neurology</i> , 2016, 87, 2317-2323.	1.1	48
395	CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. <i>Nature Communications</i> , 2016, 7, 11253.	13.2	180
396	Timing of Physical Activity, Apolipoprotein E ϵ 4 Genotype, and Risk of Incident Mild Cognitive Impairment. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 2479-2486.	2.9	25

#	ARTICLE	IF	CITATIONS
397	<i>MAPT</i> haplotype H1G is associated with increased risk of dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2016, 12, 1297-1304.	0.7	32
398	Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry. <i>Movement Disorders</i> , 2016, 31, 989-994.	4.3	35
399	Association of Mild Cognitive Impairment With Exposure to General Anesthesia for Surgical and Nonsurgical Procedures. <i>Mayo Clinic Proceedings</i> , 2016, 91, 208-217.	2.8	58
400	Updated TDP-43 in Alzheimer's disease staging scheme. <i>Acta Neuropathologica</i> , 2016, 131, 571-585.	7.9	263
401	Suspected non-Alzheimer disease pathophysiology "concept and controversy. <i>Nature Reviews Neurology</i> , 2016, 12, 117-124.	10.0	242
402	Cascading network failure across the Alzheimer's disease spectrum. <i>Brain</i> , 2016, 139, 547-562.	8.0	423
403	Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. <i>Lancet Neurology</i> , The, 2016, 15, 56-64.	10.4	108
404	Frailty and Mortality Outcomes in Cognitively Normal Older People: Sex Differences in a Population-Based Study. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 132-137.	2.9	50
405	Effect of intellectual enrichment on AD biomarker trajectories. <i>Neurology</i> , 2016, 86, 1128-1135.	1.1	72
406	Decline in Weight and Incident Mild Cognitive Impairment. <i>JAMA Neurology</i> , 2016, 73, 439.	9.3	92
407	Influence of amyloid and <i>APOE</i> on cognitive performance in a late middle-aged cohort. <i>Alzheimer's and Dementia</i> , 2016, 12, 281-291.	0.7	47
408	Longitudinal decline in mild-to-moderate Alzheimer's disease: Analyses of placebo data from clinical trials. <i>Alzheimer's and Dementia</i> , 2016, 12, 598-603.	0.7	27
409	Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 43-50.	2.6	45
410	Association Between Olfactory Dysfunction and Amnesic Mild Cognitive Impairment and Alzheimer Disease Dementia. <i>JAMA Neurology</i> , 2016, 73, 93.	9.3	311
411	Atrial fibrillation, cognitive impairment, and neuroimaging. <i>Alzheimer's and Dementia</i> , 2016, 12, 391-398.	0.7	62
412	Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community. <i>JAMA Neurology</i> , 2016, 73, 85.	9.3	164
413	Age and education corrected older adult normative data for a short form version of the Financial Capacity Instrument.. <i>Psychological Assessment</i> , 2016, 28, 737-749.	1.3	35
414	Low neural exosomal levels of cellular survival factors in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 769-773.	3.7	170

#	ARTICLE	IF	CITATIONS
415	Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer's Disease: A Diffusion Tensor Imaging Study. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 633-643.	2.7	28
416	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S63-S86.	2.7	332
417	Genetically-controlled Vesicle-Associated Membrane Protein 1 expression may contribute to Alzheimer's pathophysiology and susceptibility. <i>Molecular Neurodegeneration</i> , 2015, 10, 18.	11.8	13
418	Diabetes is Associated with Worse Executive Function in Both Eastern and Western Populations: Shanghai Aging Study and Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 167-176.	2.7	24
419	Mortality in Mild Cognitive Impairment Varies by Subtype, Sex, and Lifestyle Factors: The Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 1237-1245.	2.7	45
420	Association of Pancreatic Polypeptide with Mild Cognitive Impairment Varies by APOE ϵ 4 Allele. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 172.	3.5	6
421	Rarity of the Alzheimer Disease "Protective" APP A673T Variant in the United States. <i>JAMA Neurology</i> , 2015, 72, 209.	9.3	43
422	Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease. <i>Neurology</i> , 2015, 85, 40-47.	1.1	373
423	Mitochondrial targeting sequence variants of the CHCHD2 gene are a risk for Lewy body disorders. <i>Neurology</i> , 2015, 85, 2016-2025.	1.1	53
424	F5-04-04: Scd in a population-based sample: Progression to MCI. <i>Alzheimer's and Dementia</i> , 2015, 11, P308-P309.	0.7	0
425	Microbleeds in Atypical Presentations of Alzheimer's Disease: A Comparison to Dementia of the Alzheimer's Type. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 1109-1117.	2.7	20
426	Working memory and language network dysfunctions in logopenic aphasia: a task-free fMRI comparison with Alzheimer's dementia. <i>Neurobiology of Aging</i> , 2015, 36, 1245-1252.	3.2	87
427	2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. <i>Alzheimer's and Dementia</i> , 2015, 11, e1-120.	0.7	271
428	Clinicopathologic and ¹¹ C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. <i>Brain</i> , 2015, 138, 1370-1381.	8.0	283
429	Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. <i>Alzheimer's and Dementia</i> , 2015, 11, 865-884.	0.7	191
430	The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. <i>Alzheimer's and Dementia</i> , 2015, 11, 772-791.	0.7	84
431	Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans. <i>Alzheimer's and Dementia</i> , 2015, 11, 734-739.	0.7	89
432	Sample size calculations for clinical trials targeting tauopathies: a new potential disease target. <i>Journal of Neurology</i> , 2015, 262, 2064-2072.	3.8	10

#	ARTICLE	IF	CITATIONS
433	Frequency and topography of cerebral microbleeds in dementia with Lewy bodies compared to Alzheimer's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1101-1104.	2.2	28
434	Neuropsychiatric symptoms, ϵ -APOE ϵ 4, and the risk of incident dementia. <i>Neurology</i> , 2015, 84, 935-943.	1.1	106
435	Risk and protective factors for cognitive impairment in persons aged 85 years and older. <i>Neurology</i> , 2015, 84, 1854-1861.	1.1	66
436	Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. <i>Brain</i> , 2015, 138, 761-771.	8.0	233
437	The Human Alzheimer Disease Project. <i>JAMA Neurology</i> , 2015, 72, 626.	9.3	6
438	Age, Sex, and ϵ -APOE ϵ 4 Effects on Memory, Brain Structure, and ϵ 2-Amyloid Across the Adult Life Span. <i>JAMA Neurology</i> , 2015, 72, 511.	9.3	319
439	ϵ -APOE ϵ effect on Alzheimer's disease biomarkers in older adults with significant memory concern. <i>Alzheimer's and Dementia</i> , 2015, 11, 1417-1429.	0.7	163
440	Predicting the risk of mild cognitive impairment in the Mayo Clinic Study of Aging. <i>Neurology</i> , 2015, 84, 1433-1442.	1.1	103
441	Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials. <i>Alzheimer's and Dementia</i> , 2015, 11, 1069-1079.	0.7	22
442	Performance of the CogState computerized battery in the Mayo Clinic Study on Aging. <i>Alzheimer's and Dementia</i> , 2015, 11, 1367-1376.	0.7	96
443	White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. <i>Neurobiology of Aging</i> , 2015, 36, 2010-2017.	3.2	39
444	Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. <i>Brain</i> , 2015, 138, 3747-3759.	8.0	179
445	Multimorbidity and Risk of Mild Cognitive Impairment. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 1783-1790.	2.9	145
446	Role of ϵ 2-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. <i>JAMA Neurology</i> , 2015, 72, 1475.	9.3	23
447	Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72. <i>Acta Neuropathologica</i> , 2015, 130, 863-876.	7.9	108
448	Spectrum of cognition short of dementia. <i>Neurology</i> , 2015, 85, 1712-1721.	1.1	72
449	Self-rated and informant-rated everyday function in comparison to objective markers of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1080-1089.	0.7	88
450	Late-onset Alzheimer disease risk variants mark brain regulatory loci. <i>Neurology: Genetics</i> , 2015, 1, e15.	2.5	66

#	ARTICLE	IF	CITATIONS
451	Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers. <i>Acta Neuropathologica</i> , 2015, 130, 559-573.	7.9	93
452	Role for the microtubule-associated protein tau variant p.A152T in risk of τ -synucleinopathies. <i>Neurology</i> , 2015, 85, 1680-1686.	1.1	31
453	GWAS of longitudinal amyloid accumulation on ¹⁸ F-florbetapir PET in Alzheimer's disease implicates microglial activation gene <i>IL1RAP</i> . <i>Brain</i> , 2015, 138, 3076-3088.	8.0	119
454	Direct medical costs and source of cost differences across the spectrum of cognitive decline: A population-based study. <i>Alzheimer's and Dementia</i> , 2015, 11, 917-932.	0.7	75
455	Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2015, 36, 452-461.	3.2	117
456	Late-onset Alzheimer's risk variants in memory decline, incident mild cognitive impairment, and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 60-67.	3.2	90
457	Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study. <i>Alzheimer's and Dementia</i> , 2015, 11, 600.	0.7	699
458	MRS in Mild Cognitive Impairment: Early Differentiation of Dementia with Lewy Bodies and Alzheimer's Disease. <i>Journal of Neuroimaging</i> , 2015, 25, 269-274.	2.0	24
459	At the interface of sensory and motor dysfunctions and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 70-98.	0.7	445
460	Abnormal daytime sleepiness in dementia with Lewy bodies compared to Alzheimer's disease using the Multiple Sleep Latency Test. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 76.	6.4	48
461	2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. <i>Alzheimer's and Dementia</i> , 2014, 10, S430-52.	0.7	65
462	Antemortem MRI findings associated with microinfarcts at autopsy. <i>Neurology</i> , 2014, 82, 1951-1958.	1.1	45
463	Association of hypometabolism and amyloid levels in aging, normal subjects. <i>Neurology</i> , 2014, 82, 1959-1967.	1.1	74
464	Early Alzheimer's Disease Neuropathology Detected by Proton MR Spectroscopy. <i>Journal of Neuroscience</i> , 2014, 34, 16247-16255.	3.8	120
465	White Matter Integrity Determined With Diffusion Tensor Imaging in Older Adults Without Dementia. <i>JAMA Neurology</i> , 2014, 71, 1547.	9.3	58
466	Association of MAPT haplotypes with Alzheimer's disease risk and MAPT brain gene expression levels. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 39.	6.4	115
467	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. <i>JAMA Neurology</i> , 2014, 71, 1394.	9.3	170
468	Association of Lifetime Intellectual Enrichment With Cognitive Decline in the Older Population. <i>JAMA Neurology</i> , 2014, 71, 1017.	9.3	169

#	ARTICLE	IF	CITATIONS
469	A Prospective Study of Chronic Obstructive Pulmonary Disease and the Risk for Mild Cognitive Impairment. <i>JAMA Neurology</i> , 2014, 71, 581.	9.3	112
470	Hypothyroidism and Risk of Mild Cognitive Impairment in Elderly Persons. <i>JAMA Neurology</i> , 2014, 71, 201.	9.3	52
471	Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2014, 35, 1483-1490.	3.2	31
472	Association of diabetes with amnestic and nonamnestic mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2014, 10, 18-26.	0.7	150
473	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 844-852.	0.7	2,006
474	Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. <i>Neurobiology of Aging</i> , 2014, 35, 2421.e13-2421.e17.	3.2	76
475	Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging. <i>Alzheimer's and Dementia</i> , 2014, 10, 779-789.	0.7	26
476	Short and long telomeres increase risk of amnestic mild cognitive impairment. <i>Mechanisms of Ageing and Development</i> , 2014, 141-142, 64-69.	4.6	35
477	Progranulin protein levels are differently regulated in plasma and CSF. <i>Neurology</i> , 2014, 82, 1871-1878.	1.1	72
478	Mild Cognitive Impairment and Mild Dementia: A Clinical Perspective. <i>Mayo Clinic Proceedings</i> , 2014, 89, 1452-1459.	2.8	251
479	Age-specific population frequencies of cerebral β -amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. <i>Lancet Neurology</i> , The, 2014, 13, 997-1005.	10.4	306
480	Frontotemporal dementia and its subtypes: a genome-wide association study. <i>Lancet Neurology</i> , The, 2014, 13, 686-699.	10.4	327
481	Association of plasma and cortical amyloid beta is modulated by <i>APOE</i> ϵ 4 status. <i>Alzheimer's and Dementia</i> , 2014, 10, e9-e18.	0.7	44
482	^{18}F -fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. <i>Neurobiology of Aging</i> , 2014, 35, 2096-2106.	3.2	111
483	Improved DTI registration allows voxel-based analysis that outperforms Tract-Based Spatial Statistics. <i>NeuroImage</i> , 2014, 94, 65-78.	4.4	159
484	Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2014, 10, S226-35.	0.7	55
485	Evaluation of memory endophenotypes for association with <i>CLU</i> , <i>CR1</i> , and <i>PICALM</i> variants in black and white subjects. <i>Alzheimer's and Dementia</i> , 2014, 10, 205-213.	0.7	40
486	Association of Mediterranean Diet with Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 271-282.	2.7	559

#	ARTICLE	IF	CITATIONS
487	ApoE variant p.V236E is associated with markedly reduced risk of Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2014, 9, 11.	11.8	59
488	Do preclinical Alzheimer's disease criteria work?. <i>Lancet Neurology</i> , The, 2013, 12, 933-935.	10.4	7
489	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , 2013, 9, 251-261.	0.7	345
490	Mild cognitive impairment due to Alzheimer disease in the community. <i>Annals of Neurology</i> , 2013, 74, 199-208.	5.8	220
491	Practice Effects and Longitudinal Cognitive Change in Normal Aging vs. Incident Mild Cognitive Impairment and Dementia in The Mayo Clinic Study of Aging. <i>Clinical Neuropsychologist</i> , 2013, 27, 1247-1264.	3.0	129
492	Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. <i>Neurology</i> , 2013, 81, 1732-1740.	1.1	183
493	AÎ² Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 209-219.	6.7	56
494	The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 270-279.	0.7	7,876
495	Alzheimer's disease: progress in prediction. <i>Lancet Neurology</i> , The, 2010, 9, 4-5.	10.4	58
496	IC-03-01: Early MCI as an imaging target: Data from the National Alzheimer's Coordinating Center. <i>Alzheimer's and Dementia</i> , 2010, 6, S58-S58.	0.7	2
497	Early Diagnosis of Alzheimers Disease: Is MCI Too Late?. <i>Current Alzheimer Research</i> , 2009, 6, 324-330.	1.5	205
498	Commentary on "A roadmap for the prevention of dementia II: Leon Thal Symposium 2008." A national registry on aging. <i>Alzheimer's and Dementia</i> , 2009, 5, 105-107.	0.7	1
499	Challenges in clinical research on Alzheimer's disease: Leon Thal's legacy. <i>Alzheimer's and Dementia</i> , 2008, 4, S88-90.	0.7	1
500	Mild Cognitive Impairment: An Overview. <i>CNS Spectrums</i> , 2008, 13, 45-53.	1.3	561
501	The current status of mild cognitive impairment"what do we tell our patients?. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 60-61.	1.4	14
502	FOR DEBATE: IS MILD COGNITIVE IMPAIRMENT A CLINICALLY USEFUL CONCEPT?. <i>International Psychogeriatrics</i> , 2006, 18, 393.	1.1	59
503	Mild Cognitive Impairment Should Be Considered for DSM-V. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2006, 19, 147-154.	2.6	61
504	Neuropathologic Features of Amnestic Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2006, 63, 665.	4.5	568

#	ARTICLE	IF	CITATIONS
505	Mild Cognitive Impairment: Where Are We?. Alzheimer Disease and Associated Disorders, 2005, 19, 166-169.	1.3	24
506	Mild Cognitive Impairment: Is it Alzheimer's disease or Not?. Journal of Alzheimer's Disease, 2005, 7, 241-245.	2.7	41
507	Mild Cognitive Impairment as a Clinical Entity and Treatment Target. Archives of Neurology, 2005, 62, 1160.	4.5	791
508	Mild cognitive impairment: Useful or not?. Alzheimer's and Dementia, 2005, 1, 5-10.	0.7	21
509	Commentary on "Diagnosis of Alzheimer's disease: Two decades of progress" Alzheimer's and Dementia, 2005, 1, 122-123.	0.7	0
510	Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment. New England Journal of Medicine, 2005, 352, 2379-2388.	30.1	1,731
511	Mild cognitive impairment clinical trials. Nature Reviews Drug Discovery, 2003, 2, 646-653.	61.5	158
512	Current Concepts in Mild Cognitive Impairment. Archives of Neurology, 2001, 58, 1985.	4.5	4,185
513	Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease. Human Genetics, 2001, 109, 646-652.	3.8	93
514	AGING, MILD COGNITIVE IMPAIRMENT, AND ALZHEIMER'S DISEASE. Neurologic Clinics, 2000, 18, 789-805.	1.9	119
515	Î±2 macroglobulin gene and Alzheimer disease. Nature Genetics, 1999, 22, 17-19.	20.4	91
516	Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. Annals of Neurology, 1998, 43, 303-310.	5.8	176
517	Free and cued selective reminding test: Moans norms. Journal of Clinical and Experimental Neuropsychology, 1997, 19, 676-691.	1.4	69
518	Aging, Memory, and Mild Cognitive Impairment. International Psychogeriatrics, 1997, 9, 65-69.	1.1	771
519	Neuropsychological tests' norms above age 55: COWAT, BNT, MAE token, WRAT-R reading, AMNART, STROOP, TMT, and JLO. Clinical Neuropsychologist, 1996, 10, 262-278.	3.0	485
520	Nimodipine in the Treatment of Probable Alzheimer's Disease. Clinical Drug Investigation, 1996, 11, 185-195.	2.2	55
521	No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Movement Disorders, 1995, 10, 566-573.	4.3	84
522	Patterns and Predictors of Institutionalization in Community-Based Dementia Patients. Journal of the American Geriatrics Society, 1994, 42, 181-185.	2.9	132

#	ARTICLE	IF	CITATIONS
523	Mayo's older americans normative studies: WAIS-R norms for ages 56 to 97. Neuropsychology, Development and Cognition Section D: the Clinical Neuropsychologist, 1992, 6, 1-30.	1.5	378
524	On the expression of H-Y antigen in transsexuals. Archives of Sexual Behavior, 1986, 15, 51-68.	2.2	7
525	Mild Cognitive Impairment: Transition from Aging to Alzheimer's Disease. , 0, , 141-151.		17